About Us
Management Team
Pipeline
CAR T-cell therapies
mAb
Technology/Platform
Technology/Platform
Manufacturing
Publication
Expanded Access
Media
Join Us
Investors
Announcements
Corporate Governance
Presentations
Webcasts
Presentations
Financial Reports
Listing Documents
IR Contact
Contact Us
EN
简
繁
EN
简
繁
EN
简
繁
About Us
Management Team
Pipeline
CAR T-cell therapies
mAb
Technology/Platform
Technology/Platform
Manufacturing
Publication
Expanded Access
Media
Join Us
Investors
Announcements
Corporate Governance
Presentations
Webcasts
Presentations
Financial Reports
Listing Documents
IR Contact
Contact Us
Presentations
Announcements
Corporate Governance
Presentations
Financial Reports
Listing Documents
IR Contact
Corporate Deck
Feb 17, 2023
CARsgen Therapeutics Corporate Deck
Download
Webcasts
Presentations
Date
Title
Jan 20, 2023
2023 ASCO GI | A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti CLDN18.2 Monoclonal Antibody (AB011), as Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors
Dec 11, 2022
2022 ASH | Phase II Study of Fully Human BCMA-Targeted CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
Sep 29, 2022
2022 CAR TCR Summit
Jun 05, 2022
2022 ASCO | Safety, Tolerability and Preliminary Efficacy Results in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma from a Phase Ib/II Study of CLDN18.2 CAR T‐cell therapy (CT041)
Jun 05, 2022
2022 ASCO | Multicenter Phase 1b Trial of Salvage CT041 CLDN18.2-specific Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma
Dec 13, 2021
2021 ASH | Sustainable Efficacy and Safety Results from LUMMICAR STUDY 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma
Dec 13, 2021
2021 ASH | Integrated Analysis of B-cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects by High-Risk Factors
Sep 19, 2021
2021 ESMO | CLDN 18.2-targeted CAR-T cell therapy (CT041) in patients with cancers of the digestive system
1